Tourmaline Bio, Inc.
TRML
$12.93
-$0.19-1.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -72.34% | -260.88% | -8.42% | -77.43% | -162.24% |
| Total Depreciation and Amortization | -18.18% | 11.11% | 42.86% | 66.67% | 120.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -105.27% | -158.94% | -105.35% | -55.76% | 1,679.05% |
| Change in Net Operating Assets | 874.75% | -420.11% | 98.78% | -155.18% | -195.19% |
| Cash from Operations | -123.34% | -334.47% | -88.73% | -293.64% | -107.98% |
| Capital Expenditure | -350.00% | -- | -- | -- | 96.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 320.92% | -- | -- | -- | -- |
| Cash from Investing | 320.90% | -68,694.12% | -77,830.77% | -786,854.17% | 7,180.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 99.97% | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.18% | -288.89% | -134.05% | -1,012.45% | 1,477.04% |
